COMPOSITION:

Triforge is a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), valsartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic.

INDICATIONS:

Triforge is indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes, and myocardial infarctions.

DOSAGE & ADMINISTRATION:

Dose once-daily. Titrate up to a maximum dose of 10/320/25 mg, TRIFORGE may be used as add-on/switch therapy for patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, and diuretics.

CONTRAINDICATIONS:

Anuria, Hypersensitivity to sulfonamide-derived drugs, Known hypersensitivity to any component of this drug.

UNDESIRABLE EFFECTS:

Increased angina and/or myocardial infarction, Impaired renal function hypersensitivity reaction, Systemic Lupus Erythematosus, Lithium interaction, Potassium abnormalities, Acute Myopia and secondary angle-closure glaucoma, Metabolic imbalances, Hypotension in Volume- or- salt- Depleted Patients angle-closure glaucoma.

Most common adverse events (≥2% incidence) are dizziness, peripheral edema, headache, dyspepsia, fatigue, muscle spasms, back pain, nausea and nasopharyngitis.

PRESENTATION:

Tablets:(amlodipine/valsartan/hydrochlorothiazide mg) 5/160/12.5, 10/160/12.5, 5/160/25, 10/160/25, 10/320/25.